Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer

✍ Scribed by Nazanin Mostafaie; Enikö Kállay; Elisabeth Sauerzapf; Elisabeth Bonner; Stefan Kriwanek; Heide S. Cross; Klaus Roland Huber; Walter Krugluger

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 89 KB
• Volume: 48
• Category: Article
• ISSN: 0899-1987
• DOI: 10.1002/mc.20510

✦ Synopsis

Abstract

There is a growing body of evidence that disturbed circadian clock gene expression is associated with tumor development and tumor progression. Based on our initial experiments demonstrating decreased period 1 (Per1) expression in colon cancer, we evaluated clock gene and estrogen receptor (ER) alpha/beta expression in colon cancer cells of primary colorectal tumors and adjacent normal colon mucosa (NM) by real‐time RT‐PCR. Analysis of gene expression in G~2~ and G~3~ colorectal tumors revealed a decrease of Per1 mRNA compared with paired NM (G~2~: 0.52‐fold; P = n.s. and G~3~: 0.48‐fold; P = 0.03). A significant gender specific difference of Per1 expression was observed in G~2~ tumors as compared with NM (female: 0.38‐fold; P = 0.004 vs. male: 0.73‐fold; P = n.s.). Expression of CLOCK was significantly elevated in G~2~ tumors of male patients (1.63‐fold, P = 0.01). The expression of ER‐beta was significantly decreased in G~2~ and G~3~ tumors (G~2~: 0.32‐fold; P = 0.003 and 0.27; P = 0.001). No significant gender specific differences of ER‐beta reduction in tumors were observed. A significant correlation between the decrease of Per1 and ER‐beta in colorectal tumors (r = 0.61; P < 0.001) was found. No changes in gene expression were detected for ER‐alpha and Per2. Our data demonstrate a correlated decrease of Per1 and ER‐beta in colorectal tumors, mediated probably by epigenetic mechanisms. The observed gender differences in the expression of CLOCK and Per1 in G~2~ tumors might suggest a gender‐specific, distinctive role of the cellular clock in colorectal tumorigenesis. © 2009 Wiley‐Liss, Inc.